Objective: Altered glutamatergic neurotransmission has been implicated in the pathogenesis
of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan …

Objective: Altered glutamatergic neurotransmission is implicated in the pathogenesis of
major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA …

Background A significant proportion of adults with major depressive disorder (MDD) do not
respond to treatments which are currently used in clinical practice such as first-generation …

Introduction The large percentage of adults with major depressive disorder (MDD)
insufficiently responding and/or tolerating conventional monoamine-based antidepressants …

An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-
methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the …

Bupropion is presumed to be a dopamine-norepinephrine reuptake inhibitor and is n
effective antidepressant. It is available as three oral formulations:(i) bupropion immediate …

BACKGROUND:: Major depressive disorder (MDD) is a common psychiatric condition, with
6.6% of the adult population in the United States experiencing a major depressive episode …

Background: This was the first controlled continuation phase study (up to 1-year total
treatment) to evaluate the safety and efficacy of bupropion SR for decreasing the risk for …

This series of studies was undertaken to assess the safety profile of sustainedrelease (SR)
bupropion in the treatment of depressed outpatients. Adults with a diagnosis of major …

Bupropion has been used as an antidepressant for over 20 years, though its licence for such
use varies and it is typically a third-or fourth-line agent. It has a unique pharmacology …